vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $20.0M, roughly 1.1× AGIOS PHARMACEUTICALS, INC.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -541.1%, a 548.3% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 86.1%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 56.1%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
AGIO vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $21.9M |
| Net Profit | $-108.0M | $1.6M |
| Gross Margin | 90.6% | — |
| Operating Margin | -608.9% | 9.0% |
| Net Margin | -541.1% | 7.2% |
| Revenue YoY | 86.1% | 1292.3% |
| Net Profit YoY | -11.9% | 116.7% |
| EPS (diluted) | $-1.86 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | $21.9M | ||
| Q3 25 | $12.9M | $2.1M | ||
| Q2 25 | $12.5M | $3.0M | ||
| Q1 25 | $8.7M | $421.0K | ||
| Q4 24 | $10.7M | $1.6M | ||
| Q3 24 | $9.0M | $3.3M | ||
| Q2 24 | $8.6M | $2.7M | ||
| Q1 24 | $8.2M | $1.7M |
| Q4 25 | $-108.0M | $1.6M | ||
| Q3 25 | $-103.4M | $-7.4M | ||
| Q2 25 | $-112.0M | $-8.5M | ||
| Q1 25 | $-89.3M | $-12.3M | ||
| Q4 24 | $-96.5M | — | ||
| Q3 24 | $947.9M | $-8.7M | ||
| Q2 24 | $-96.1M | $-10.2M | ||
| Q1 24 | $-81.5M | $-12.3M |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 92.3% | — |
| Q4 25 | -608.9% | 9.0% | ||
| Q3 25 | -907.4% | -353.4% | ||
| Q2 25 | -1020.1% | -292.3% | ||
| Q1 25 | -1222.0% | -2921.4% | ||
| Q4 24 | -1165.3% | — | ||
| Q3 24 | -1146.9% | -264.2% | ||
| Q2 24 | -1228.3% | -390.6% | ||
| Q1 24 | -1124.3% | -737.8% |
| Q4 25 | -541.1% | 7.2% | ||
| Q3 25 | -803.1% | -346.6% | ||
| Q2 25 | -899.4% | -287.1% | ||
| Q1 25 | -1023.3% | -2911.4% | ||
| Q4 24 | -899.6% | — | ||
| Q3 24 | 10574.7% | -259.6% | ||
| Q2 24 | -1115.7% | -382.7% | ||
| Q1 24 | -995.8% | -719.1% |
| Q4 25 | $-1.86 | $0.05 | ||
| Q3 25 | $-1.78 | $-0.07 | ||
| Q2 25 | $-1.93 | $-0.09 | ||
| Q1 25 | $-1.55 | $-0.17 | ||
| Q4 24 | $-1.44 | — | ||
| Q3 24 | $16.22 | $-0.17 | ||
| Q2 24 | $-1.69 | $-0.20 | ||
| Q1 24 | $-1.45 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $26.4M |
| Total Assets | $1.3B | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | $27.1M | ||
| Q3 25 | $92.7M | $11.7M | ||
| Q2 25 | $80.9M | $27.5M | ||
| Q1 25 | $79.0M | $13.1M | ||
| Q4 24 | $76.2M | $22.5M | ||
| Q3 24 | $253.7M | $32.4M | ||
| Q2 24 | $84.5M | $30.0M | ||
| Q1 24 | $118.8M | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $1.2B | $26.4M | ||
| Q3 25 | $1.3B | $13.2M | ||
| Q2 25 | $1.4B | $18.2M | ||
| Q1 25 | $1.5B | $6.6M | ||
| Q4 24 | $1.5B | $17.5M | ||
| Q3 24 | $1.6B | $25.4M | ||
| Q2 24 | $660.5M | $21.6M | ||
| Q1 24 | $743.9M | $30.0M |
| Q4 25 | $1.3B | $42.2M | ||
| Q3 25 | $1.4B | $31.6M | ||
| Q2 25 | $1.5B | $40.7M | ||
| Q1 25 | $1.6B | $22.3M | ||
| Q4 24 | $1.7B | $32.2M | ||
| Q3 24 | $1.8B | $44.8M | ||
| Q2 24 | $773.1M | $42.3M | ||
| Q1 24 | $849.7M | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $-1.1M |
| Free Cash FlowOCF − Capex | $-97.3M | — |
| FCF MarginFCF / Revenue | -487.5% | — |
| Capex IntensityCapex / Revenue | 5.6% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | $-1.1M | ||
| Q3 25 | $-88.2M | $-9.0M | ||
| Q2 25 | $-77.1M | $-3.4M | ||
| Q1 25 | $-111.5M | $-8.2M | ||
| Q4 24 | $-133.2M | $-36.3M | ||
| Q3 24 | $-84.2M | $-7.5M | ||
| Q2 24 | $-72.6M | $-10.0M | ||
| Q1 24 | $-99.9M | $-9.8M |
| Q4 25 | $-97.3M | — | ||
| Q3 25 | $-89.7M | — | ||
| Q2 25 | $-78.0M | $-3.4M | ||
| Q1 25 | $-112.3M | $-8.3M | ||
| Q4 24 | $-134.1M | $-36.4M | ||
| Q3 24 | $-84.6M | $-7.5M | ||
| Q2 24 | $-72.7M | $-10.0M | ||
| Q1 24 | $-100.0M | $-9.8M |
| Q4 25 | -487.5% | — | ||
| Q3 25 | -696.5% | — | ||
| Q2 25 | -626.2% | -116.5% | ||
| Q1 25 | -1286.4% | -1976.7% | ||
| Q4 24 | -1250.1% | -2309.3% | ||
| Q3 24 | -944.2% | -225.7% | ||
| Q2 24 | -844.4% | -376.2% | ||
| Q1 24 | -1221.2% | -573.0% |
| Q4 25 | 5.6% | 0.0% | ||
| Q3 25 | 12.1% | 0.0% | ||
| Q2 25 | 7.0% | 0.9% | ||
| Q1 25 | 8.8% | 35.6% | ||
| Q4 24 | 9.0% | 4.2% | ||
| Q3 24 | 4.7% | 0.0% | ||
| Q2 24 | 1.8% | 0.4% | ||
| Q1 24 | 1.7% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGIO
Segment breakdown not available.
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
